Skip to Content

Fintepla (fenfluramine) Disease Interactions

There are 11 disease interactions with Fintepla (fenfluramine):

Major

Fenfluramine (Includes Fintepla) cardiac disease

Major Potential Hazard, Moderate plausibility. Applies to: Valvular Heart Disease

Serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine have been associated with valvular heart disease. Exercise care when using this agent in patients with cardiac disease. Cardiac monitoring is required prior to starting, during, and after treatment. If valvular heart disease is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment. Echocardiograms should be repeated every six months, and once 3-6 months posttreatment.

Major

Fenfluramine (Includes Fintepla) pulmonary disease

Major Potential Hazard, Moderate plausibility. Applies to: Pulmonary Hypertension

Serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine, have been associated with pulmonary arterial hypertension. Exercise care when using this agent in patients with pulmonary disease. Cardiac monitoring is required before starting, during, and after treatment. Cardiac monitoring via echocardiogram can identify evidence of pulmonary arterial hypertension. If pulmonary arterial hypertension is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment. Echocardiograms should be repeated every six months, and once 3-6 months posttreatment.

Moderate

Antiepileptics (Includes Fintepla) suicidal tendency

Moderate Potential Hazard, Moderate plausibility. Applies to: Psychosis, Depression

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs across multiple indications in either monotherapy or adjunctive therapy for a median treatment duration of 12 weeks (up to a maximum of 24 weeks) showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. The estimated rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% for 16,029 placebo-treated patients, representing an increase of approximately one case for every 530 patients treated. There were four suicides in AED-treated patients and none in placebo-treated patients, although the number is too small to establish any causal relationship. The increased risk of suicidal thoughts or behavior was observed as early as one week after starting AEDs and persisted for the duration of treatment assessed. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Therapy with AEDs should be administered cautiously in patients with depression or other psychiatric disorders. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. For clinically significant or persistent symptoms, a dosage reduction or treatment withdrawal should be considered. If patients have symptoms of suicidal ideation or behavior, treatment should be discontinued.

Moderate

CNS stimulants (Includes Fintepla) bipolar disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Bipolar Disorder

Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression). Close monitoring is recommended when using these agents in patients with bipolar disorders.

Moderate

CNS stimulants (Includes Fintepla) psychotic disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Psychosis

Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. Close monitoring is recommended when using these agents in patients with psychotic disorders.

Moderate

Fenfluramine (Includes Fintepla) alcoholism

Moderate Potential Hazard, Moderate plausibility. Applies to: Alcoholism

Fenfluramine can cause somnolence, sedation, and lethargy. Central nervous system depressants, including alcohol, could potentiate these effects. Exercise caution when using this agent in alcoholic patients or those at risk of sedation. Close monitoring is advised. Advise patients not to drive or operate machinery until they know how this drug will affect them.

Moderate

Fenfluramine (Includes Fintepla) anorexia

Moderate Potential Hazard, Moderate plausibility. Applies to: Weight Loss/Failure to Thrive, Malnourished

Fenfluramine can cause decreases in appetite and weight. Exercise care when using this agent in patients at risk of decreased appetite or weight. It is recommended to monitor the growth of pediatric patients carefully. Weight should be monitored regularly during treatment, and dose modifications should be considered if a decrease in weight is observed.

Moderate

Fenfluramine (Includes Fintepla) hypertension

Moderate Potential Hazard, Moderate plausibility. Applies to: Hypertension

Fenfluramine can cause an increase in blood pressure. Exercise care when using this agent in hypertensive patients. It is recommended to monitor blood pressure in patients treated with fenfluramine.

Moderate

Fenfluramine (Includes Fintepla) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Fenfluramine is primarily metabolized to norfenfluramine by CYP450 1A2, CYP450 2B6, and CYP450 2D6. The use of fenfluramine in patients with hepatic impairment is not recommended.

Moderate

Fenfluramine (Includes Fintepla) renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Most of an orally administered dose of fenfluramine (greater than 90%) is excreted in the urine as fenfluramine, norfenfluramine, or other metabolites. The use of fenfluramine in patients with moderate or severe renal impairment is not recommended.

Moderate

Fenfluramine (Includes Fintepla) visual disturbance

Moderate Potential Hazard, Moderate plausibility. Applies to: Visual Defect/Disturbance

Fenfluramine can cause mydriasis and can precipitate angle-closure glaucoma. Exercise care when using this agent in patients with visual disturbances. Consider discontinuing treatment in patients with acute decrease in visual acuity or ocular pain.

Fintepla (fenfluramine) drug interactions

There are 305 drug interactions with Fintepla (fenfluramine)

Fintepla (fenfluramine) alcohol/food interactions

There are 2 alcohol/food interactions with Fintepla (fenfluramine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.